Printer Friendly

CYTRX CORPORATION ANNOUNCES PATIENT ENROLLMENT FOR NEW RHEOTHRX(R) INJECTION CLINICAL TRIAL

 NORCROSS, Ga., March 17 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) announced today that patient enrollment had begun in a new clinical trial investigating the efficacy and safety of RheothRx(R) Injection in patients with suspected acute myocardial infarction (heart attack).
 This study is planned for 250 patients and is being conducted by Burroughs Wellcome Co. which licensed RheothRx Injection from CytRx in 1990.
 "This study has very important implications as it addresses a segment of the heart attack population that currently goes untreated," said Jack J. Luchese, CytRx president and chief executive officer. "Each year over 1 million patients are hospitalized for heart attack, however, only about 25 percent receive drug therapy due to lack of definitive diagnosis or fear of complications."
 Two other studies investigating RheothRx Injection in heart attack patients have been in progress since March 1992 and are now nearing completion. Additionally, studies investigating RheothRx Injection in vaso-occlusive crisis associated with sickle cell disease as well as in acute cerebral malaria are ongoing.
 CytRx Corporation is engaged in the research and development of critical care pharmaceutical products for the treatment of vascular and infectious diseases, burns and cancer. Vetlife(TM), a CytRx subsidiary, is developing feed additives to enhance growth in food animals. Vaxcel(TM), a second subsidiary, is developing an advanced vaccine adjuvant system for human and veterinary use.
 Burroughs Wellcome Co. is a research-based pharmaceutical company with headquarters in Research Triangle Park, N.C.
 -0- 3/17/93
 /CONTACT: CytRx Corporation public relations, 404-368-9500/
 (CYTR)


CO: CytRx Corporation; Burroughs Wellcome Company ST: Georgia, North Carolina IN: MTC SU:

RA-TG -- AT005 -- 7054 03/17/93 12:38 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1993
Words:271
Previous Article:NEW YORK STOCK EXCHANGE CLOSING, TUESDAY, MARCH 16 /PRN/
Next Article:ARGONNE TO DEVELOP NEW SOFTWARE TO HELP DESIGN HIGH-EFFICIENCY HEAT PUMP
Topics:


Related Articles
CYTRX CORPORATION ANNOUNCES THE BEGINNING OF PHASE II TRIALS OF RHEOTHRX(R) INJECTION
CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION FOR SICKLE CELL
CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION FOR SICKLE CELL
FIRST OF TWO RHEOTHRX(R) STUDIES REPORTED: 9,000-PATIENT PHASE III STUDY IN ACUTE MYOCARDIAL INFARCTION PLANNED
CYTRX FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR MULTIPLE DRUG RESISTANT CANCER TREATMENT
CYTRX ANNOUNCES RHEOTHRX STEERING COMMITTEE RECOMMENDATION EXPECTED IN OCTOBER
CYTRX ANNOUNCES TERMINATION OF GLAXO WELLCOME RHEOTHRX DEVELOPMENT PROGRAM
CytRx Corporation Presents at BIO 1998 Investor and Partnering Conference
CYTRX CLINICAL TRIAL OF ARIMOCLOMOL FOR ALS SHOWS PROMISE.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters